Mitsubishi UFJ Trust & Banking’s Cytokinetics CYTK Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$562K	Buy	+6,593	New	+$473K	﹤0.01%	1031

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CYTK Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Cytokinetics (CYTK) in Q2 2026: 6,593 shares worth $562K. The stake represents ﹤0.01% of the portfolio and ranks #1031 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 6,593 shares of Cytokinetics worth $562K as of Q2 2026.
Cytokinetics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Cytokinetics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1031 holding.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.